Get started
Author

Bryant Barnes

Observed names: B Barnes, B. Barnes, Barnes, Bryant
Observed institution: BeOne Medicines (Switzerland)
ORCID: 0000-0002-1090-1959
Observed ORCID: 0000-0002-1090-1959
OpenAlex ID: A5047613440
Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies
2025 · Kevin C. Mange, Daniel Serrano, et al. · Journal of Patient-Reported Outcomes · 4
PDF
PCR140 Psychometric Validation of the QOL-B Respiratory Domain in Adults with Newly Diagnosed or Recurrent Mycobacterium avium Complex (MAC) Lung Disease: The ARISE and ENCORE Studies
2024 · KC Mange, D Serrano, et al. · Value in Health · 2
PDF
Change in Patient Reported Respiratory Symptoms in a Randomized, Double-blind, Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease: The ARISE Study
2024 · C.L. Daley, D. Serrano, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Validation of a respiratory symptom score from the Quality of Life-Bronchiectasis Questionnaire in adults with Mycobacterium avium complex lung disease
2026 · Daniel Serrano, Mariam Hassan, et al. · Patient Related Outcome Measures · 1
PCR196 Psychometric Validation of the PROMIS Fatigue-Short Form 7A in Adults with Newly Diagnosed or Recurrent Mycobacterium avium Complex (MAC) Lung Disease: The ARISE and ENCORE Studies
2024 · KC Mange, D Serrano, et al. · Value in Health · 1
PDF
Msr3 a Novel Multivariate Application of Profile Analysis to Characterize Multidomain Patient-reported Outcome (pro) Patterns in Patients With Gastric or Gastroesophageal Junction (gc/gejc) Adenocarcinoma
2026 · Marcia Cruz-Correa, Joselyn Angeles-Figueroa, et al. · Value in Health
A novel Bayesian approach for assessing associations between ECOG performance status (ECOG-PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (GC/GEJC) adenocarcinoma: Post hoc analysis from the RATIONALE-305 trial.
2026 · Marcia Roxana Cruz-Correa, Markus H. Moehler, et al. · Journal of Clinical Oncology
Associations between ECOG performance status (PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (G/CEJC) adenocarcinoma: Results from the RATIONALE-305 trial.
2026 · Marcia Roxana Cruz-Correa, Markus H. Moehler, et al. · Journal of Clinical Oncology
PCR97 Recurrent Patient-Reported Outcome (PRO)-Based Symptomatic Deterioration Predicts Survival and Disease Progression in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC): Post-Hoc Analysis of RATIONALE-315
2025 · Dongsheng Yue, Changli Wang, et al. · Value in Health
PCR221 Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality of Life (HRQoL) Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2025 · Ying Cheng, Tai Qin, et al. · Value in Health
PCR65 Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality of Life (HRQoL) Outcomes in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): The Rationale-306 Study
2024 · J. Xu, P. Jiménez-Fonseca, et al. · Value in Health
1449P Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
2024 · M. Moehler, D. Serrano, et al. · Annals of Oncology
PDF
1213P Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
2024 · F. Cappuzzo, C. Wang, et al. · Annals of Oncology
PDF
P57 Mapping Quality of Life - Alzheimer's Disease (QOL-AD) Scores to EQ-5D-5L Utilities in the Ambar Trial Population
2022 · C Simons, D Gomez-Ulloa, et al. · Value in Health
Works count: 16
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type